{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:09:11Z","timestamp":1771373351607,"version":"3.50.1"},"reference-count":100,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T00:00:00Z","timestamp":1555286400000},"content-version":"vor","delay-in-days":2175,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Portuguesa de Cardiologia"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.repc.2012.11.002","type":"journal-article","created":{"date-parts":[[2013,4,23]],"date-time":"2013-04-23T20:15:28Z","timestamp":1366748128000},"page":"395-409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Cardiotoxicidade associada \u00e0 terap\u00eautica oncol\u00f3gica: mecanismos fisiopatol\u00f3gicos e estrat\u00e9gias de preven\u00e7\u00e3o"],"prefix":"10.1016","volume":"32","author":[{"given":"Rui","family":"Ad\u00e3o","sequence":"first","affiliation":[]},{"given":"Gilles","family":"de Keulenaer","sequence":"additional","affiliation":[]},{"given":"Adelino","family":"Leite-Moreira","sequence":"additional","affiliation":[]},{"given":"Carmen","family":"Br\u00e1s-Silva","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.repc.2012.11.002_bib0005","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1253\/circj.CJ-10-0632","article-title":"Cardiovascular side-effects of modern cancer therapy","volume":"74","author":"Minami","year":"2010","journal-title":"Circ J"},{"key":"10.1016\/j.repc.2012.11.002_bib0010","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: Incidence, pathogenesis, diagnosis, and management","volume":"53","author":"Yeh","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2012.11.002_bib0015","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.pharmthera.2009.10.002","article-title":"Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy","volume":"125","author":"Raschi","year":"2010","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.repc.2012.11.002_bib0020","first-page":"525","article-title":"Cost of cancer care in Portugal","volume":"22","author":"Ara\u00fajo","year":"2009","journal-title":"Acta Med Port"},{"key":"10.1016\/j.repc.2012.11.002_bib0025","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ejca.2009.12.014","article-title":"Estimates of cancer incidence and mortality in Europe in 2008","volume":"46","author":"Ferlay","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.repc.2012.11.002_bib0030","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1188\/08.CJON.627-638","article-title":"Cardiovascular toxicity associated with cancer treatment","volume":"12","author":"Viale","year":"2008","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.repc.2012.11.002_bib0035","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrcardio.2010.121","article-title":"Cardiotoxicity of anticancer treatments: What the cardiologist needs to know","volume":"7","author":"Ewer","year":"2010","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.repc.2012.11.002_bib0040","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0014-2565(01)71381-1","article-title":"Cardiotoxicity of 5-fluorouracil: Ischemia or myocardial toxicity?","volume":"201","author":"L\u00f3pez Medrano","year":"2001","journal-title":"Rev Clin Esp"},{"key":"10.1016\/j.repc.2012.11.002_bib0045","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4330\/wjc.v2.i9.270","article-title":"Neoplastic pericardial disease: Old and current strategies for diagnosis and management","volume":"2","author":"Lestuzzi","year":"2010","journal-title":"World J Cardiol"},{"key":"10.1016\/j.repc.2012.11.002_bib0050","doi-asserted-by":"crossref","first-page":"842","DOI":"10.7326\/0003-4819-135-9-200111060-00021","article-title":"Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia","volume":"135","author":"Barbey","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.repc.2012.11.002_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/eurjhf\/hfq213","article-title":"Cardiovascular side effects of cancer therapies: A position statement from the Heart Failure Association of the European Society of Cardiology","volume":"13","author":"Eschenhagen","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2012.11.002_bib0060","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.repc.2012.11.002_bib0065","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jnci\/djp440","article-title":"Cardiotoxicity of anticancer drugs: The need for cardio-oncology and cardio-oncological prevention","volume":"102","author":"Albini","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.repc.2012.11.002_bib0070","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2","article-title":"A clinicopathologic analysis of adriamycin cardiotoxicity","volume":"32","author":"Lefrak","year":"1973","journal-title":"Cancer"},{"key":"10.1016\/j.repc.2012.11.002_bib0075","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","article-title":"Type II chemotherapy-related cardiac dysfunction: Time to recognize a new entity","volume":"23","author":"Ewer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.repc.2012.11.002_bib0080","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment","volume":"23","author":"Ewer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.repc.2012.11.002_bib0085","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1200\/JCO.2007.11.0106","article-title":"Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility","volume":"25","author":"Telli","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.repc.2012.11.002_bib0090","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1200\/JCO.1998.16.11.3502","article-title":"Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer","volume":"16","author":"Ryberg","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.repc.2012.11.002_bib0095","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1200\/JCO.2005.12.121","article-title":"Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia","volume":"23","author":"Lipshultz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.repc.2012.11.002_bib0100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/1097-0142(19890101)63:1<37::AID-CNCR2820630106>3.0.CO;2-Z","article-title":"Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma","volume":"63","author":"Hortobagyi","year":"1989","journal-title":"Cancer"},{"key":"10.1016\/j.repc.2012.11.002_bib0105","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2001.19.1.191","article-title":"Anthracycline-induced clinical heart failure in a cohort of 607 children: Long-term follow-up study","volume":"19","author":"Kremer","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.repc.2012.11.002_bib0110","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pcad.2010.06.007","article-title":"Mechanisms of anthracycline cardiac injury: Can we identify strategies for cardioprotection?","volume":"53","author":"Sawyer","year":"2010","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.repc.2012.11.002_bib0115","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1096\/fasebj.4.13.2210154","article-title":"Doxorubicin cardiotoxicity: Analysis of prevailing hypotheses","volume":"4","author":"Olson","year":"1990","journal-title":"FASEB J"},{"key":"10.1016\/j.repc.2012.11.002_bib0120","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1073\/pnas.87.11.4275","article-title":"Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro","volume":"87","author":"Ito","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.repc.2012.11.002_bib0125","doi-asserted-by":"crossref","first-page":"5828","DOI":"10.1074\/jbc.272.9.5828","article-title":"Molecular mechanisms of doxorubicin-induced cardiomyopathy. Selective suppression of Reiske iron-sulfur protein, ADP\/ATP translocase, and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes","volume":"272","author":"Jeyaseelan","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.repc.2012.11.002_bib0130","doi-asserted-by":"crossref","first-page":"8290","DOI":"10.1074\/jbc.M308033200","article-title":"Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes","volume":"279","author":"Lim","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.repc.2012.11.002_bib0135","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1254\/jjp.76.405","article-title":"Effects of in vitro and in vivo exposure to doxorubicin (adriamycin) on caffeine-induced Ca2+ release from sarcoplasmic reticulum and contractile protein function in \u2018chemically-skinned\u2019 rabbit ventricular trabeculae","volume":"76","author":"Takahashi","year":"1998","journal-title":"Jpn J Pharmacol"},{"key":"10.1016\/j.repc.2012.11.002_bib0140","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/path.1863","article-title":"Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin","volume":"207","author":"Lebrecht","year":"2005","journal-title":"J Pathol"},{"key":"10.1016\/j.repc.2012.11.002_bib0145","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0167-5273(94)90061-2","article-title":"Properties of G-protein modulated receptor-adenylyl cyclase system in myocardium of spontaneously hypertensive rats treated with adriamycin","volume":"44","author":"Fu","year":"1994","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.repc.2012.11.002_bib0150","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1172\/JCI116379","article-title":"Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in a chronic rabbit model","volume":"91","author":"Dodd","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.repc.2012.11.002_bib0155","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/CIRCULATIONAHA.109.895771","article-title":"Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function","volume":"121","author":"De Angelis","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2012.11.002_bib0160","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.2174\/092986709788186228","article-title":"New developments in anthracycline-induced cardiotoxicity","volume":"16","author":"Mordente","year":"2009","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.repc.2012.11.002_bib0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0305-7372(83)80029-2","article-title":"4\u2019-epi-doxorubicin, a new analogue of doxorubicin: A preliminary overview of preclinical and clinical data","volume":"10","author":"Ganzina","year":"1983","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.repc.2012.11.002_bib0170","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF00172021","article-title":"Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies","volume":"4","author":"Ganzina","year":"1986","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.repc.2012.11.002_bib0175","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2174\/092986706776055751","article-title":"Prodrugs of anthracyclines in cancer chemotherapy","volume":"13","author":"Kratz","year":"2006","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.repc.2012.11.002_bib0180","first-page":"CD005006","article-title":"Different anthracycline derivates for reducing cardiotoxicity in cancer patients","author":"van Dalen","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.repc.2012.11.002_bib0185","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s12012-007-0015-3","article-title":"Role of anthracyclines in the era of targeted therapy","volume":"7","author":"Cort\u00e9s-Funes","year":"2007","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.repc.2012.11.002_bib0190","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.drudis.2011.09.015","article-title":"Liposomal drug formulations in cancer therapy: 15 years along the road","volume":"17","author":"Slingerland","year":"2012","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.repc.2012.11.002_bib0195","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0076-6879(05)91004-5","article-title":"The liposomal formulation of doxorubicin","volume":"391","author":"Abraham","year":"2005","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.repc.2012.11.002_bib0200","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12012-007-0010-8","article-title":"Ongoing phase I and II studies of novel anthracyclines","volume":"7","author":"Sessa","year":"2007","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.repc.2012.11.002_bib0205","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2005.05759.x","article-title":"Protecting against anthracycline-induced myocardial damage: A review of the most promising strategies","volume":"131","author":"Wouters","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.repc.2012.11.002_bib0210","first-page":"53","article-title":"A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine","volume":"10","author":"Myers","year":"1983","journal-title":"Semin Oncol"},{"key":"10.1016\/j.repc.2012.11.002_bib0215","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1200\/JCO.2004.03.086","article-title":"Antioxidants and cancer therapy: A systematic review","volume":"22","author":"Ladas","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.repc.2012.11.002_bib0220","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1200\/JCO.2002.04.178","article-title":"2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology","volume":"20","author":"Schuchter","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.repc.2012.11.002_bib0225","first-page":"43","article-title":"Adult multicenter trials using dexrazoxane to protect against cardiac toxicity","volume":"25","author":"Swain","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1016\/j.repc.2012.11.002_bib0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1634\/theoncologist.2008-0137","article-title":"Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: Review and expert recommendations","volume":"14","author":"Martin","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.repc.2012.11.002_bib0235","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1200\/JCO.1997.15.4.1333","article-title":"Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy","volume":"15","author":"Swain","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.repc.2012.11.002_bib0240","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2012.11.002_bib0245","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdr348","article-title":"Trastuzumab-related cardiotoxicity in the elderly: A role for cardiovascular risk factors","volume":"23","author":"Serrano","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.repc.2012.11.002_bib0250","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/378394a0","article-title":"Requirement for neuregulin receptor erbB2 in neural and cardiac development","volume":"378","author":"Lee","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.repc.2012.11.002_bib0255","doi-asserted-by":"crossref","first-page":"10261","DOI":"10.1074\/jbc.273.17.10261","article-title":"Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes","volume":"273","author":"Zhao","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.repc.2012.11.002_bib0260","doi-asserted-by":"crossref","first-page":"8880","DOI":"10.1073\/pnas.122249299","article-title":"Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy","volume":"99","author":"Ozcelik","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.repc.2012.11.002_bib0265","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nm0502-459","article-title":"ErbB2 is essential in the prevention of dilated cardiomyopathy","volume":"8","author":"Crone","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.repc.2012.11.002_bib0270","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1161\/CIRCULATIONAHA.107.690487","article-title":"Role of neuregulin-1\/ErbB signaling in cardiovascular physiology and disease: Implications for therapy of heart failure","volume":"116","author":"Lemmens","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2012.11.002_bib0275","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejheart.2006.05.010","article-title":"Serum HER2 levels are increased in patients with chronic heart failure","volume":"9","author":"Perik","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2012.11.002_bib0280","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/eurjhf\/hfq152","article-title":"Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses","volume":"13","author":"Jabbour","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.repc.2012.11.002_bib0285","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11523-011-0203-8","article-title":"Heart to heart with trastuzumab: A review on cardiac toxicity","volume":"6","author":"Di Cosimo","year":"2011","journal-title":"Target Oncol"},{"key":"10.1016\/j.repc.2012.11.002_bib0290","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2012.11.002_bib0295","first-page":"60","article-title":"Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)","volume":"26","author":"Sliwkowski","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/j.repc.2012.11.002_bib0300","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.4161\/cc.7.12.6016","article-title":"Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells","volume":"7","author":"Shell","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.repc.2012.11.002_bib0305","doi-asserted-by":"crossref","first-page":"10607","DOI":"10.1073\/pnas.0701286104","article-title":"Activation of AMP-activated protein kinase by human EGF receptor 2\/EGF receptor tyrosine kinase inhibitor protects cardiac cells","volume":"104","author":"Spector","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.repc.2012.11.002_bib0310","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2217\/fca.11.54","article-title":"Cardio-oncology in targeting the HER receptor family: The puzzle of different cardiotoxicities of HER2 inhibitors","volume":"7","author":"Albini","year":"2011","journal-title":"Future Cardiol"},{"key":"10.1016\/j.repc.2012.11.002_bib0315","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0022-2828(03)00145-7","article-title":"NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy","volume":"35","author":"Nakagami","year":"2003","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.repc.2012.11.002_bib0320","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2012.11.002_bib0325","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00109-008-0323-5","article-title":"New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone","volume":"86","author":"Lemari\u00e9","year":"2008","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.repc.2012.11.002_bib0330","first-page":"70","article-title":"Trastuzumab-induced cardiac dysfunction: A \u2018dual-hit\u2019","volume":"16","author":"Zeglinski","year":"2011","journal-title":"Exp Clin Cardiol"},{"key":"10.1016\/j.repc.2012.11.002_bib0335","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1200\/JCO.2005.04.1764","article-title":"Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer","volume":"24","author":"Robert","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.repc.2012.11.002_bib0340","doi-asserted-by":"crossref","first-page":"341","DOI":"10.7150\/ijms.5.341","article-title":"XeNA: Capecitabine plus docetaxel, with or without trastuzumab, as preoperative therapy for early breast cancer","volume":"5","author":"Gl\u00fcck","year":"2008","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.repc.2012.11.002_bib0345","first-page":"666","article-title":"Adjuvant therapy for HER2 positive breast cancer: Are anthracyclines still necessary?","volume":"6","author":"Castrellon","year":"2008","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.repc.2012.11.002_bib0350","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1021\/ar700108g","article-title":"Targeted cancer therapy: Conferring specificity to cytotoxic drugs","volume":"41","author":"Chari","year":"2008","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.repc.2012.11.002_bib0355","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate","volume":"68","author":"Lewis Phillips","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.repc.2012.11.002_bib0360","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2010.29.5865","article-title":"Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy","volume":"29","author":"Burris","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.repc.2012.11.002_bib0365","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa053028","article-title":"Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer","volume":"354","author":"Joensuu","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2012.11.002_bib0370","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1056\/NEJM199405053301802","article-title":"C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer","volume":"330","author":"Muss","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2012.11.002_bib0375","first-page":"1107","article-title":"HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil","volume":"8","author":"Di Leo","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.repc.2012.11.002_bib0380","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1080\/02841860500543182","article-title":"TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer","volume":"45","author":"Villman","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1016\/j.repc.2012.11.002_bib0385","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1200\/JCO.2007.14.6597","article-title":"Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial","volume":"26","author":"Bartlett","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.repc.2012.11.002_bib0390","first-page":"e148","volume":"116","author":"Anderson","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2012.11.002_bib0395","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1161\/01.CIR.0000133187.74800.B9","article-title":"Cardiovascular complications of cancer therapy: Diagnosis, pathogenesis, and management","volume":"109","author":"Yeh","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2012.11.002_bib0400","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00432-007-0250-9","article-title":"Cardiotoxicity of fluoropyrimidines in different schedules of administration: A prospective study","volume":"134","author":"Kosmas","year":"2008","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.repc.2012.11.002_bib0405","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab","volume":"99","author":"Scappaticci","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.repc.2012.11.002_bib0410","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.breast.2010.11.002","article-title":"Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues","volume":"20","author":"Zambelli","year":"2011","journal-title":"Breast"},{"key":"10.1016\/j.repc.2012.11.002_bib0415","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/europace\/eup300","article-title":"Introducing a new entity: Chemotherapy-induced arrhythmia","volume":"11","author":"Guglin","year":"2009","journal-title":"Europace"},{"key":"10.1016\/j.repc.2012.11.002_bib0420","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.athoracsur.2010.03.100","article-title":"Risk factors for atrial fibrillation after lung cancer surgery: Analysis of the Society of Thoracic Surgeons general thoracic surgery database","volume":"90","author":"Onaitis","year":"2010","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.repc.2012.11.002_bib0425","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/annonc\/mdn713","article-title":"Management of hypertension in angiogenesis inhibitor-treated patients","volume":"20","author":"Izzedine","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.repc.2012.11.002_bib0430","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/annonc\/mdn637","article-title":"Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab","volume":"20","author":"Scartozzi","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.repc.2012.11.002_bib0435","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.repc.2012.11.002_bib0440","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000073282","article-title":"Thalidomide and thrombosis","volume":"33","author":"Rodeghiero","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1016\/j.repc.2012.11.002_bib0445","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1378\/chest.06-2360","article-title":"Risk of thrombosis with lenalidomide and its prevention with aspirin","volume":"131","author":"Hirsh","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.repc.2012.11.002_bib0450","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/cncr.20347","article-title":"The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review","volume":"101","author":"Deitcher","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.repc.2012.11.002_bib0455","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/cncr.24219","article-title":"A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health","volume":"115","author":"Ewer","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.repc.2012.11.002_bib0460","doi-asserted-by":"crossref","first-page":"317659","DOI":"10.4061\/2011\/317659","article-title":"Radiation-induced heart disease: A clinical update","volume":"2011","author":"Yusuf","year":"2011","journal-title":"Cardiol Res Pract"},{"key":"10.1016\/j.repc.2012.11.002_bib0465","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0046-8177(96)90447-5","article-title":"Pathology of radiation-induced heart disease: A surgical and autopsy study of 27 cases","volume":"27","author":"Veinot","year":"1996","journal-title":"Hum Pathol"},{"key":"10.1016\/j.repc.2012.11.002_bib0470","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1001\/jama.1993.03510160067031","article-title":"Factors affecting late mortality from heart disease after treatment of Hodgkin's disease","volume":"270","author":"Hancock","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.repc.2012.11.002_bib0475","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.drudis.2008.06.011","article-title":"Preclinical assessment of cardiac toxicity","volume":"13","author":"Kettenhofen","year":"2008","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.repc.2012.11.002_bib0480","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/bjp.2008.249","article-title":"Zebrafish: An emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery","volume":"154","author":"Barros","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.repc.2012.11.002_bib0485","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1542\/peds.2007-0575","article-title":"Monitoring for cardiovascular disease in survivors of childhood cancer: Report from the Cardiovascular Disease Task Force of the Children's Oncology Group","volume":"121","author":"Shankar","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.repc.2012.11.002_bib0490","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s00246-010-9878-3","article-title":"Anthracycline-associated cardiotoxicity in survivors of childhood cancer","volume":"32","author":"Trachtenberg","year":"2011","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.repc.2012.11.002_bib0495","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1470-2045(09)70042-7","article-title":"Cardiovascular toxicity caused by cancer treatment: Strategies for early detection","volume":"10","author":"Altena","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.repc.2012.11.002_bib0500","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.jacc.2007.09.061","article-title":"Unlocking the mysteries of diastolic function: Deciphering the Rosetta Stone 10 years later","volume":"51","author":"Lester","year":"2008","journal-title":"J Am Coll Cardiol"}],"container-title":["Revista Portuguesa de Cardiologia"],"original-title":[],"language":"pt","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255113000334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255113000334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:01:11Z","timestamp":1760108471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0870255113000334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":100,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0870255113000334"],"URL":"https:\/\/doi.org\/10.1016\/j.repc.2012.11.002","relation":{},"ISSN":["0870-2551"],"issn-type":[{"value":"0870-2551","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiotoxicidade associada \u00e0 terap\u00eautica oncol\u00f3gica: mecanismos fisiopatol\u00f3gicos e estrat\u00e9gias de preven\u00e7\u00e3o","name":"articletitle","label":"Article Title"},{"value":"Revista Portuguesa de Cardiologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.repc.2012.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espa\u00f1a, S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}